Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China
- PMID: 33886411
- PMCID: PMC8381821
- DOI: 10.1080/21645515.2021.1913964
Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China
Abstract
This study explored the safety of COVID-19 vaccine (Aikewei) and the role of clinical pharmacists in the implementation of COVID-19 vaccination. A total of 2305 hospital employees in Children's Hospital of Fudan University in Shanghai, China received the COVID-19 vaccine. The whole process of vaccination was monitored by clinical pharmacists, and the occurrence, types, severity of adverse reactions were recorded in detail. Through the investigation and analysis on the safety of COVID-19 vaccination of the 2305 people, the important role and value of clinical pharmacists in the vaccination process was elaborated. Common adverse reactions included local pain, dizziness and fatigue, with the incidence rates of 2.09%, 0.67% and 0.49%, respectively. Others such as headache, nausea, skin itching, cough, palpitation, dry mouth, hand anesthesia, local induration, muscle soreness, local rash, and chill had incidence rates of less than 0.30%. Three cases of serious adverse events that occurred in this vaccination returned to normal after treatment, with no subsequent discomfort. Clinical pharmacists played an important role in the safety monitoring of COVID-19 vaccination. The safety of the inactivated COVID-19 vaccine is good. Most of the common adverse reactions were mild and tolerable, with generally low incidence. The work of clinical pharmacists is important and can be expanded in the future to ensure the safety of vaccination and to provide better health care service.
Keywords: COVID-19; clinical pharmacists; safety; vaccine.
Similar articles
-
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1. Trials. 2021. PMID: 33849629 Free PMC article.
-
Safety monitoring in inactivated COVID-19 vaccines by clinical pharmacists from a single center in China.Front Immunol. 2022 Sep 5;13:882919. doi: 10.3389/fimmu.2022.882919. eCollection 2022. Front Immunol. 2022. PMID: 36131922 Free PMC article.
-
Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.J Korean Med Sci. 2021 Nov 22;36(45):e318. doi: 10.3346/jkms.2021.36.e318. J Korean Med Sci. 2021. PMID: 34811980 Free PMC article.
-
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Review.
-
COVID-19 vaccines: concerns beyond protective efficacy and safety.Expert Rev Vaccines. 2021 Aug;20(8):1013-1025. doi: 10.1080/14760584.2021.1949293. Epub 2021 Jul 5. Expert Rev Vaccines. 2021. PMID: 34180347 Review.
Cited by
-
Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis.J Headache Pain. 2022 Mar 31;23(1):41. doi: 10.1186/s10194-022-01400-4. J Headache Pain. 2022. PMID: 35361131 Free PMC article.
-
Self-Reported adverse events among Chinese healthcare workers immunized with COVID-19 vaccines composed of inactivated SARS-CoV-2.Hum Vaccin Immunother. 2022 Nov 30;18(5):2064134. doi: 10.1080/21645515.2022.2064134. Epub 2022 Apr 22. Hum Vaccin Immunother. 2022. PMID: 35452357 Free PMC article.
-
Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis.Vaccines (Basel). 2022 Apr 12;10(4):596. doi: 10.3390/vaccines10040596. Vaccines (Basel). 2022. PMID: 35455344 Free PMC article. Review.
-
Safety and Adverse Events Related to Inactivated COVID-19 Vaccines and Novavax;a Systematic Review.Arch Acad Emerg Med. 2022 Jul 7;10(1):e54. doi: 10.22037/aaem.v10i1.1585. eCollection 2022. Arch Acad Emerg Med. 2022. PMID: 36033990 Free PMC article. Review.
-
SARS-CoV-2 Vaccine Uptake among Patients with Chronic Liver Disease: A Cross-Sectional Analysis in Hebei Province, China.Vaccines (Basel). 2023 Jul 28;11(8):1293. doi: 10.3390/vaccines11081293. Vaccines (Basel). 2023. PMID: 37631861 Free PMC article.
References
-
- World Health Organization . Coronavirus disease dashboard; 2021Jan 28 [accessed 2021 Jan 29]. https://covid19.who.int.
-
- Li J, Ao N, Yin J, Wang S, Feng Y, He Y, Li Y, Yang S. Analysis on the willingness of COVID-19 vaccination and influencing factors among the patient in outpatient clinic in Kunming. Chin J Public Health. Forthcoming. doi:10.11847/zgggws1133368. - DOI
-
- National Medicine Products Administration . China grants conditional approval for first COVID vaccine. Beijing (China): China Daily; 2020Dec 31 [accessed 2021 Jan 29]. http://english.nmpa.gov.cn/2020-12/31/c_579192.htm.
-
- Beijing Institute of Biological Products Co. Ltd . Package insert of COVID-19 vaccine (vero cell), inactivated. Beijing (China); 2020Dec 30 [accessed 2021 Jan 29]. https://wwwbjbpicom/?p=75.
-
- National Medical Products Administration . Notice of CDE on issuing the five guiding principles of the research and development of preventive vaccines in novel coronavirus (trial) (No. 21 in 2020). Beijing (China): Center for Drug Evaluation; 2020Aug 14 [accessed 2021 Jan 29]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20200814230916157.html.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical